In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Gets Into Hot Water

Executive Summary

The $100 million consent decree that Abbott Diagnostics signed with the Food and Drug Administration in early November took many in the diagnostics industry by surprise and has left them shaken.
Advertisement

Related Content

Diagnostic Products Corp.: Thriving, For Now
Lonza Biologics: Responding to Changing Needs
Diagnostic Products Corp.: Thriving, For Now
I-Stat's $60 Million Gamble
Post Abbott Consent Decree; A Changed World for Immunoassay Vendors
Credible Competition for Roche In Molecular Diagnostics
How's Diagnostics Doing? Quite Well, Thank You
Vysis's Ship Comes In
Big Diagnostics Companies See the Genomics Light
The Boom in Prion Testing

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001069

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel